Stocktoria
CytomX Therapeutics, Inc. CTMX
CytomX Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M | $100.4M | $57.5M | $59.5M | $71.6M | $15.0M |
| R&D expense | $68.7M | $83.4M | $77.7M | $111.6M | $114.2M | $112.9M | $131.6M | $103.9M | $92.3M | $54.8M |
| Operating income | -$22.4M | $25.0M | -$6.5M | -$101.3M | -$116.0M | -$48.6M | -$110.9M | -$77.9M | -$46.3M | -$59.6M |
| Interest expense | — | — | — | — | — | — | — | — | — | $1.7M |
| Income tax | $238,000 | $224,000 | $3.9M | $0 | $0 | -$13.9M | -$427,000 | $14.3M | -$513,000 | -$19,000 |
| Net income | -$17.4M | $31.9M | -$569,000 | -$99.3M | -$115.9M | -$32.9M | -$102.2M | -$84.6M | -$43.1M | -$58.9M |
| Operating cash flow | -$75.6M | -$86.2M | -$56.0M | -$110.8M | -$119.0M | $5.3M | -$140.5M | -$75.5M | $170.4M | -$2.0M |
| Free cash flow | -$75.8M | -$86.5M | -$56.9M | -$112.5M | -$120.6M | $3.0M | -$144.0M | -$79.3M | $168.8M | -$4.2M |
| Cash & equivalents | $12.7M | $38.1M | $17.2M | $193.7M | $205.5M | $191.9M | $188.4M | $247.6M | $177.5M | $104.6M |
| Total assets | $151.6M | $120.5M | $201.8M | $260.9M | $339.4M | $358.7M | $341.3M | $457.1M | $397.6M | $199.1M |
| Total liabilities | $52.6M | $121.0M | $249.2M | $346.6M | $339.9M | $308.9M | $290.2M | $326.2M | $327.7M | $120.6M |
| Shareholders' equity | $99.0M | -$456,000 | -$47.4M | -$85.8M | -$459,000 | -$7.8M | $51.1M | $130.9M | $69.9M | $78.5M |
Growth · year-over-year · Revenue CAGR 19.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -44.8% | +36.4% | +90.4% | +42.5% | -62.8% | +74.6% | -3.4% | -16.9% | +376.1% | +95.1% |
| Net income growth | -154.5% | — | — | — | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | — | -4189.5% | — | — | -147.0% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.